Absorb GT1 Bioresorbable Vascular Scaffold (BVS) System

Absorbable Coronary Drug-eluting Stent

FDA Premarket Approval P150023 S010

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

Approval for implementation of everolimus bht manufactured at a new manufacturing site.

DeviceAbsorb GT1 Bioresorbable Vascular Scaffold (BVS) System
Classification NameAbsorbable Coronary Drug-eluting Stent
Generic NameAbsorbable Coronary Drug-eluting Stent
ApplicantABBOTT VASCULAR INC.
Date Received2018-03-01
Decision Date2018-05-30
PMAP150023
SupplementS010
Product CodePNY
Docket NumberPremarket Approval (PMA) // Quick Links: Skip To Main Page Content Skip To Search Skip To Topics Menu Skip To Common Links U.S. Food & Drug Administration   Follow FDA En Español Search FDA   Home Food Drugs Medical Devices Radia
Advisory CommitteeCardiovascular
Supplement TypeNormal 180 Day Track
Supplement ReasonProcess Change - Manufacturer/sterilizer/packager/supplier
Expedited ReviewNo
Combination Product Yes
Applicant Address ABBOTT VASCULAR INC. 3200 Lakeside Drive santa Clara, CA 95054

Supplemental Filings

Supplement NumberDateSupplement Type
P150023Original Filing
S010 2018-03-01 Normal 180 Day Track
S009 2017-05-17 30-day Notice
S008 2017-04-14 30-day Notice
S007 2017-03-13 135 Review Track For 30-day Notice
S006 2016-10-24 30-day Notice
S005 2016-09-08 30-day Notice
S004
S003 2016-08-05 Normal 180 Day Track No User Fee
S002 2016-07-29 Special (immediate Track)
S001 2016-07-11 Normal 180 Day Track

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.